Bavarian Nordic Boosts Production of Monkeypox Vaccine

Paul Chaplin, CEO Bavarian Nordic announced during a call with investors that the company has leaned heavily into production of bulk Jynneos, its monkeypox vaccine. The news comes shortly after the company made a deal with Grand River Aseptic Manufacturing to fill vials from bulk vaccine in the US. Bavarian Nordic is now dedicating all of its production capacity to Jynneos, sidelining its other vaccines

According to Angus Liu, “Now facing increased Jynneos demand, the company is hiring more people to boost bulk production and fill-finish capacity, which was just endorsed by the FDA. It’s also working to outsource production of its RSV vaccine candidate, which is currently in phase 3 testing. The measures are helping BN double bulk yield to four batches a week by the end of this year, Chaplin said. The Danish company also recently contracted Grand River Aseptic, which Chaplin said could double the fill-finish capacity of Jynneos, with the potential for further increase.”

To read more, click here.

(Source: Fierce Pharma, August 24th, 2022)